Synchron Research acquires Innovance, a start-up Ahmedabad based Contract Research Organization. The deal was facilitated by Deloitte.

Innovance has built an impressive world-class clinical research facility at Ahmedabad. This acquisition has provided Synchron an edge in offering excellent internationally accepted clinical research facility. The new clinical facility is spread over 18,000 sq.ft on a single floor, with three different volunteer housing areas. Also the facility has 14 beds state-of the-art Phase I facility. The other two volunteer housing areas has 32 beds each. This new 80 beds will be in addition to already existing 90 beds in the existing facility and 30 beds Bangkok facility, totaling to 200 beds across Asia. This makes Synchron one of the largest Asian CRO. Synchron BA/BE business has broad base loyal client franchise with repeat business with about 75% Europe/USA clients who will be further assured with this new facility offering international level clinical research facility.

This acquisition is first of its kind in CRO space in India. “Synchron is looking for more important acquisitions in India and other parts of Asia in future to increase our Asian foot-print to provide more research offerings to our clients” said Dr. Shivprakash, Chairman and Managing Director of Synchron.

Synchron is the first privately held CRO to be started in India in 1998 and partnered with PAREXEL, a leading International CRO in 2006. Synchron has built an industry leading reputation as a premiere CRO by providing drug development services to domestic and international clients with consistent quality and newer capabilities.

Bio-Innova offers a wide range of professional services from clinical research, pharmacokinetics, bioavailability, bioequivalence, bioanalysis, and statistics to data management. Our scientific experts and quality assurance teams are committed to serve our client's need in the field of pharmaceutical, biotechnology, food and medical devices. We value close collaborative partnership, and assist our clients to control costs, accelerate time-to-market, minimize risks and maximise return on investment.

PharmAlliance 2005 Awards were announced on the occasion of Global PharmAlliance 2005 conference organised by Frost & Sullivan in Mumbai last week. The Partner of Choice 2005 awards were given to the Custom Research and Manufacturing Service providers (CRAMS) who have shown prominence in their respective categories. Partner of Choice for Drug Discovery in CNS was presented to Suven Life Sciences, Limited. Partner of Choice for Clinical Research went to iGATE Clinical Research International, Partner of Choice for BA/BE studies to Synchron Research Services Pvt. Limited and Partner of Choice for Corporate Excellence was given to Orchid Chemicals and Pharmaceuticals Limited.

Synchron Research Pvt Ltd, a leading contract research organization in the country has teamed-up with Symogen a UK-based pharmacovigilance company for effective implementation of Pharmacovigilance activities and set up an independent unit for commencing the services in India for the first time in the country. The company has also entered into a strategic partnership with the US-based Parexel International to monitor clinical trial sites in India, Malaysia, Nepal, Sri Lanka and Pakistan.

The Rs 6-crore Ahmedabad-based Synchron commenced its operations in Bangalore two years ago. "The facility in Bangalore will conduct phase II to phase IV studies and investment of around Rs 1 crore has been made to install the software and hardware including MedDRA and WHO dictionary to speed-up its clinical research and data management studies" said Dr. Shivprakash, managing director, Synchron Research Services Pvt Ltd.

As a first step on its association with Symogen, Synchron had organized a one-day seminar on Pharmacovigilance in Bangalore for clinical investigators, pharma companies, regulatory affairs personnel, academicians and pharmacists to apprise on the recent developments.

Symogen team is here in India to train the staff at Synchron for causality assessment, coding and statistical analysis. Symogen will bring in their strengths of pharmacovigilance services to India through Synchron, stated Dr. Arun Biswas director, Symogen.

Synchron in India, offers clinical registration of new pharmaceutical products and medical devices, from phase I to phase IV, including Bioequivalence, Bioavailability, Pharmacokinetic/Pharmacodynamic studies, Statistical Analysis and Data Management strictly adhering to ICH and GCP guidelines. It also provides clinical trial services to domestic and international pharmaceutical and biopharmaceutical companies.

The US-based Parexel plays a key role in clinical development services for pharmaceutical biotechnology and medical device industry to help clients to reduce the time to market development control costs.

Boston, MA, - PAREXEL International Corporation (Nasdaq: PRXL) announced its strategic collaboration with Synchron Research Services Private Limited, a privately held contract research organization headquartered in Ahmedabad, India.

Under the alliance, PAREXEL will leverage Synchron's capabilities to benefit bio/pharmaceutical clients with enhanced access to geographic coverage and multi-patient recruitment capabilities in India and Bangalore. The alliance also provides Synchron's customers access to the clinical trial expertise and project management skills of PAREXEL, one of the world's largest bio/pharmaceutical outsourcing providers. "The collaboration with Synchron expands our global clinical research services into regions that expedite drug development success for our clients," said Josef H. von Rickenbach, PAREXEL's Chairman and Chief Executive Officer. "Our alliance with an established company headquartered in India underscores PAREXEL's commitment to providing clients with enhanced drug development services in emerging markets."

"Through our alliance with PAREXEL, we can now offer clients an enhanced portfolio of clinical development solutions," stated Dr. Shivprakash, M.Pharm, Ph.D., Chief Executive Officer, Synchron Research. "Our synergistic approach provides clients with enhanced clinical capabilities and strategies, enabling them to accelerate crucial time to market."